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HUMAN PAPILLOMAVIRUS: PATHOGENESIS AND BARRIERS TO  
 
PREVENTION 
 
 
SNEH PATEL 
 
 
ABSTRACT 
 
 
Cervical cancer is one of the most common forms of cancer in the world, and human 
papillomavirus (HPV) is a cause of the vast majority of these patient cases. With many 
HPV types being oncogenic in nature, HPV as a whole is responsible for over 5% of all 
cancers worldwide and 15% of cancer in women in developing countries. HPV is a 
sexually transmitted infection that is spread through contact with infected genital skin, 
mucosa, or bodily fluids from a partner with acute or subclinical viral infection. While 
less frequent, various strains of the virus are also responsible for anal and vaginal warts, 
anal cancer, and cancer of the vulva and penis – these account for approximately 50,000 
cases per year worldwide. Data also suggest a potential implication of HPV in 
oropharyngeal cancers, especially among younger adults.  
 
Various behavioral and prophylactic approaches are recommended for the prevention of 
HPV infection and cancer. For example, there is evidence that behavioral change can be 
effective, such as condom use and limitation on the number of sexual partners. Besides 
this, in recent years we have seen the development of various prophylactic or therapeutic 
vaccines that are highly effective in the prevention of HPV pathogenesis. Despite this, 
barriers to treatment and prevention exist, making HPV a continuing threat to individuals 
	 vi	
most at-risk across the globe. Thus, this study reviewed a large collection of current HPV 
and related cancer literature to understand the process of infection and pathogenesis in 
various human sites as well as potential barriers to prevention and treatment that may be 
perpetuating the survival of the virus across the world. Analyzing current and past 
research on such barriers, this paper delves into important variables that can affect early 
detection and treatment of HPV, and also explores a novel and promising therapy 
currently in development that could be valuable in overcoming many of these issues.  
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I. INTRODUCTION 
 
Background Virology 
 
 
Papillomaviruses are a large group of viruses that have machinery to infect both humans 
and animals alike. These viral agents belong to the Papovaviradae family, a group of 
viruses that are often linked to neoplasms found in mammals (Vambutas, DeVoti, & 
Nouri 2005). Physiologically, HPV presents as a non-enveloped virus with a relatively 
small diameter of 55 nanometers (Lyon, 2007). Its capsid is icosahedral in shape and is 
composed of 72 capsomeres that are formed by varying distributions of two cap proteins, 
usually being five molecules of pentameric major cap protein L1 and twelve molecules of 
minor cap protein L2 (Lyon, 2007). 
 
The virus contains a double stranded DNA genome organized in a circular shape, which 
can be described in three parts  (Stanley, 2012). The first region is a 400-1000 base pair 
long region known as the noncoding regulatory region or the upper regulatory region 
(Syrjänen & Syrjänen, 1999). This region, denoted in yellow in the model proposed by 
Stanley 2012 (Figure 1), contains the p97 core promoter needed to initiate transcription, 
making it the regulatory point for viral gene expression. This region also accounts for the 
highest degree of genomic variation, which allows for the existence of various viral types 
(Syrjänen & Syrjänen, 1999).  The second region is often referred to as the early region, 
denoted in blue (Figure 1), and consists of open reading frames E1 through E7, which 
code for viral oncogenes needed for replication and oncogenesis (Richart et al, 1998). 
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Finally, the late region, denoted in green (Figure 1), encodes for the L1 and L2 structural 
capsid proteins (Zheng, Gharizadeh, & Wallin, 2007). 
 
          
 
Figure 1. Genome of the HPV16 viroid. The upper regulatory region (URR, yellow) is the 
initiation site for transcription as it contains the p97 core promoter. The early region genes (blue) 
and late region genes (green) are transcribed, allowing for packaging of a new viroid progenitor 
while inside the host cell. Function of each gene as listed. Figure taken from Stanley, 2012. 
 
 
 
Early region genes are transcribed first, and viral E2’s main function is to inhibit the virus 
expressing high levels of oncogenes E6 and E7 when the virus is free-floating, or is not 
currently in a state of replication (Munger et al, 1989). This changes once a host cell is 
infected and viral transcription is necessary - E2 function becomes suppressed, allowing 
for expression of E6 and E7 (Munger et al, 1989). This upregulation of E6 and E7 levels 
is key to tumor formation because the two function to inactivate tumor suppressor genes 
p53 and pRb, two proteins that act as the body’s control switch for committing the cell to 
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mitosis and cellular proliferation (Munger et al, 1989). Specifically, E6 inhibits the 
function of p53 by marking it for ubiquitination, while E7 inhibits the function of pRb by 
forming a bound inactive complex with the protein (Munger et al, 1989). Together, this 
allows downstream proteins usually inhibited by pRb and p53 when cellular proliferation 
is not desired to be free to function, causing the promotion of growth in an uncontrolled 
manner (Munger et al, 1989). 
 
Uncontrolled Growth – pRb Cascade 
 
Inhibition of pRb leads to tumor formation by forcing the cell through the mitotic G1-S 
checkpoint (Sherr & McCormick, 2002). The pRb protein regulates this checkpoint and 
consequently overall mitotic activity by binding and inhibiting the e2F transcription 
factor when growth is not needed, arresting the cell and preventing it from transcribing 
the genes needed to pass through this checkpoint in order to commit to growth (Figure 2, 
right). However, when a healthy cell needs to proliferate, pRb is phosphorylated by the 
cyclin-dependent kinase (CDK) 4/6 enzymes, which are usually under inhibition by a p53 
pathway product when growth is not needed, as discussed in the next section (Al-Khalaf 
et al, 2017). Phosphorylation of pRb by CDK/cyclin causes a conformational change that 
alters the pRb-e2F binding pocket and unlocks e2F, allowing it to promote growth 
(Figure 2 left).  
 
The classical model of cellular transcription assumes that post-translational modifications 
to transcriptional inhibitor(s) by enzymes causes release of the inhibitor(s) from bound 
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transcription factors that function to activate G1-S checkpoint promoting genes (Bertoli 
et al, 2013). In the case of the HPV cycle, CDK kinases target the transcriptional inhibitor 
pRb, and by phosphorylating this protein, they inactivate and release it from the e2F 
transcription factor. With e2F free to interact with DNA, this process culminates in the 
transcription of downstream G1-S promoting genes in a positive feedback loop (Bertoli et 
al, 2013). Through a secondary and not entirely understood pathway, e2F also promotes 
growth by releasing the p16INK4A tumor suppressor protein from basal inhibition (Al-
Khalaf et al, 2017). This is paradoxical given that tumor suppressor class proteins like 
p53 and pRb usually function to inhibit growth, but nevertheless activation of p16INK4A 
leads to increased mitosis levels in tandem with activation of G1-S checkpoint promoting 
genes (Al-Khalaf et al, 2017).  
 
When mitosis and cellular growth are no longer necessary, pRb is dephosphorylated and 
methylated by Set7/9 enzymes, reversing the effect of the CDK kinases and returning 
pRb to its original state, that is, being able to bind and inhibit e2F (Munro, Carr & La 
Thangue, 2012). This causes cellular growth to be inhibited once again (Figure 2).  
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Figure 2. Summary of the pRb cellular signaling pathway. Interplay between pRb activation 
by phosphorylation via CDK/cyclin and inactivation by methylation via Set enzymes. These post-
translational modifications alter functionality of pRb, promoting and inhibiting cellular growth 
respectively. When DNA damage is detected or when the cell does not have any need to undergo 
mitosis, the Set7/9 pathway trumps CDK/cyclin activity because these enzymes are inhibited by 
the p53 pathway product p21. This allows Set enzymes to freely methylate pRb, inhibiting growth 
and promoting arrest to allow for time to fix the damage or promote apoptosis. Figure adapted 
from Munro, Carr & La Thangue, 2012.  
 
 
 
Constitutive inhibition of pRb, which would allow free function of e2F without any 
regulation at the cellular level, has been observed to occur through a multitude of 
mutagenic processes: gene deletion, promoter deletion, accelerated degradation, loss of 
function mutations, or in the case of HPV - viral products binding pRb and displacing 
e2F to allow the protein to be free of inhibition (White et al, 2014, Figure 3 right). While 
this replicates the growth effect by allowing e2F to be free from pRb’s binding inhibition, 
the ability to prevent cellular overgrowth is lost due to the constitutive binding of pRb to 
	 6	
E7 through the same binding pocket that pRb uses to bind e2F, leading to the formation 
of a hyperproliferative and cancerous host cell (White et al, 2014). 
 
 
                       
 
  
Figure 3. Interference of tumor suppressor genes p53 and pRb by viral E6 and E7. Once 
transcribed, viral oncogenes interfere with p53 and pRb pathways. The E7 oncogene forcefully 
binds to pRb to prevent formation of a pRb-e2F complex, which normally inhibits proliferation. 
The E6 oncogene marks p53 with a six-ubiquitin tag that targets it for degradation by the 26S 
proteosome, preventing p53’s inhibition on growth (via upegulation of p21 and inhibition of 
CDK/cyclin that allow e2F to function freely by displacing pRb from it). Through blockage of 
these tumor suppressor pathways, the E6 and E7 oncogenes allow for uncontrolled growth, 
eventually leading to the formation of a lesion that can become a tumor if not managed properly. 
Figure adapted from Yim & Park, 2005.  
 
 
 
Uncontrolled Growth – p53 Cascade 
 
 
In times of growth, p53 activity is at a low level because one of its functions is to 
upregulate MDM2, which in turn binds and inhibits p53 in a negative feedback loop, 
allowing the cell to proliferate (Figure 4). When DNA damage is detected and 
proliferation needs to be halted, MDM2 is post-translationally modified, allowing p53 to 
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activate other tumor suppressor proteins, namely p21. The p21 protein functions to inhibit 
enzymes key in allowing the cell through the G1-S pathway (Al-Khalaf et al, 2017). 
Specifically, p21 directly inhibits CDK 4/6 activity and also indirectly decreases their 
activity levels through a negative feedback loop by upregulating pRb (Figure 2). In 
essence, p53 promotes cellular senescence (arrest) by releasing its downstream product 
p21 in order to inhibit the G1-S checkpoint-promoting enzymes of the pRb cascade, 
buying time for repair mechanisms to fix the damage or promote apoptosis if it is too 
grave (Al-Khalaf et al, 2017). 
 
In some mutagenic states, oncogenes can upregulate MDM2, which would increase 
degradation of p53 and consequently prevent release of p21, allowing CDK 4/6 to freely 
function in promoting growth (Al-Khalaf et al, 2017). In the case of HPV, viral E6 has 
been demonstrated to ubiquitinate the p53 tumor suppressor with a 6-ubiquitin tag, which 
attracts the 26S proteasome and causes it to degrade p53, preventing its function entirely 
(Figure 3 left). Working in tandem with viral E7 displacing e2F, without pRb or p21 
interfering with the pathway and inhibiting the function of e2F, the protein is free to 
promote constitutive growth and hyperproliferation (White et al, 2014). Given this 
cascade overlap, inhibition of p53 is crucial for transforming a cell into a 
hyperproliferative state, which explains why loss of p53 function is a common mutation 
found in the majority of cancer cases, regardless of tissue type (Sherr & McCormick, 
2002). 
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Figure 4. Summary of the p53 pathway and interplay with pRb. When cellular damage is 
detected, the p53 pathway works to promote cellular arrest through interplay with the pRb 
pathway. Detection of DNA damage causes a decrease in levels of MDM2, removing the negative 
feedback on p53 and leading to activation of p21. High levels of p21 will then both directly and 
indirectly inhibit the activity of cyclin/CDK that phosphorylate pRb, in turn preventing the cell 
from passing the G1-S checkpoint and achieving further growth. Mutagens, including those of 
viruses, take advantage of this pathway at various entry points to negate the effects of p53 
causing activation of p21 and pRb inhibiting e2F by binding. Regardless of where in the pathway 
they are introduced, mutagens aim to prevent the tumor suppressors from binding and inhibiting 
the function of e2F, which is a requisite step for unchecked growth. Figure adapted from Lonning 
& Knappskog, 2013. 
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Worldwide Relevance of Oncogenic HPV 
 
There are more than 200 genomically unique HPVs specific to humans as hosts, and 
transmission most notably occurs through skin-to-skin contact during intercourse (Lasker 
& Swain, 2015). Because of this, HPV is one of the most commonly transmitted 
infections – in fact, research suggests that the majority of sexually active people in the 
USA are infected with one or more HPVs at some point in their lives (Wilson et al, 
2016), and HPV accounts for the highest proportion of sexually transmitted infections on 
an annual basis (Palefsky et al, 1991). Between 2011-2014, the prevalence of genital 
HPV infection was recorded to be 45.2% of men and 39.9% of women domestically 
irrespective of race, and of those, 25.1% of all male cases (11.35% of entire male 
population) and 20.4% of all female cases (8.14% of entire female population) involved 
high-risk oncogenic strains that are known to cause cancer. Oral infection presented in 
7.3% of individuals, and 4.0% of those were high-risk cases (McQuillian, 2017). 
Prevalence rates have been recorded to be highest in Black, White, and Hispanic persons, 
while the lowest rates were seen in Asians (McQuillian, 2017). While incidence of oral 
HPV has risen over the past decade, through vaccination and screening, genital incidence 
has continually decreased over time (Lasker & Swain, 2015). 
 
Some HPVs, like strains 6 and 11, are low-risk and only cause warts that are usually 
cleared through natural cell-mediated immunity (Wilson et al, 2016).. However, there 
also exist high-risk oncogenic HPVs, like strains 16 and 18, which are known to cause 
cancer (Wilson et al, 2016). Viruses in general are suspected in nearly one third of all 
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cancer cases (33.2%), and high-risk HPV accounts for 5% of all cases (Fidler et al, 2012). 
While many high-risk infections can often occur without symptoms and clear naturally, 
in some instances, high-risk infection can cause lesions that do progress to cancer. 
Oncogenic HPV types can develop into a variety of cancers, but are most often linked to 
cervical cancer, with 70% of all cervical cases being due to HPV 16 and 18 (Palefsky et 
al, 1991). Similarly, anal cancer (85% of all cases due to HPV 16) and oropharyngeal 
cancer are also linked to high risk HPV (Villa et al, 2005) 
 
While research has shown that prevention via sexual barriers and vaccination is crucial to 
preventing transmission, there are currently no treatments or cures for acute infection 
(Fenkl, 2016).  
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Specific Aims 
 
Specific aims of the following thesis include: 
1. To review of past and present literature to illuminate the molecular pathways 
and clinical manifestations of abnormal squamous epithelial cells as a result of 
HPV infection 
2. To investigate the patterns of viral pathogenesis and subsequent histological 
changes seen in tumorigenic host cells, which collectively lead to cancer 
3. Exploration of current prevention and treatment measures and both tangible 
and perceived barriers that potential patients face in obtaining acute care and 
vaccine coverage 
4. Presentation on a novel treatment measure that may prove beneficial in 
bolstering coverage rates, including a discussion on some potential obstacles 
for uptake  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 12	
II. CLINICAL OUTCOMES 
 
 
Long-Term Risks 
 
 
In males, HPV is known to cause cancers of anal, penile, and oropharyngeal surfaces 
such as the throat, tongue, and tonsillary regions. Males are especially at risk for 
oropharyngeal malignancies, with prevalence being much higher in males than females 
(Panchaud et al, 2000). In the US alone, over 5500 cases of oropharyngeal cases are seen 
annually, which accounts for over 78% of male HPV-related cancers (Figure 5). Thus, 
HPV is suspected in nearly 8 of 10 oropharyngeal cancer cases, and it is predicted that 
these cancers may exceed annual cervical cancer rates by 2020 (Panchaud et al, 2000). 
Although incidence rates of oropharyngeal cancer have changed little in the past three 
decades, the percentage of related oral tumors containing HPV DNA has risen from 
16.3% between 1984-1987 to 71.7% between 2000-2004 (Chaturvedi et al, 2011). 
According to the CDC, over 50% of male cases occur among youth ages of 15-24, thus it 
is postulated that the college population is especially at risk (Panchaud et al, 2000). 
Nevertheless, this is problematic because risk factors for HPV-related oral cancer remain 
largely inferential.  
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Figure 5. Worldwide burden of HPV-related cancers. Annual deaths due to each HPV-related 
cancer described in thousands. Of note, men are much more at risk for oropharyngeal cases than 
females. Original data collected from the International Association for Research on Cancer 
(IARC) Globocan 2008 (4.5-2011), figure taken from Gillison et al, 2014.  
 
 
 
In females, vulvular, oropharyngeal, and anal cancers are possible outcomes of HPV 
infection, but the major risk is cervical cancer. Cervical cancer accounts for the second 
most common cancer in low-income countries; age-adjusted incidence rates showing 
between 10 cases per 100,000 individuals in industrialized countries and up to 40 cases 
per 100,000 individuals in developing countries annually (Ferlay et al, 2010). However, 
the disease burden has been high for many decades, so we have seen a a strong drive for 
making screening technologies readily available in the recent past; because of these 
efforts, we have now reached the point that we are able to diagnose 4 of 5 new cases that 
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appear in developing countries worldwide (Ferlay et al, 2010). Such findings highlight 
the importance of early detection and treatment of infection (Ferlay et al, 2010). 
 
 
Research shows 493,000 new cases of cervical cancer annually across the globe (Ferlay 
et al, 2010). With 4 of 5 patient deaths occurring within developing countries, cervical 
cancer is a substantial problem for low and middle-income countries (Ferlay et al, 2010). 
Many countries within Asia, among other developing regions, face a huge risk for HPV-
induced cancer - in 2010, over 25% of the global burden of cervical cancer occurred 
solely in India (Ferlay et al, 2010). The region of Southeast Asia as a whole had almost 
three times the number of cases as the next most highly affected continent of Africa, 
largely due to its large population and especially the lack of access to the healthcare 
infrastructure needed for rapid diagnostic and follow-up screening (Ferlay et al, 2010). 
 
The epidemiology orf anal and oral cancer is also increasingly understood throughout the 
world. Oral cancer is currently the sixth leading cancer observed worldwide (Torre et al, 
2012). Though less common an outcome than cervical cancer, a large proportion of HPV-
related oral and anal cancer cases are also thought to be preventable, so understanding the 
dynamics of infection in these sites is equally as important (Kramer et al, 2011).  
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RISK FACTORS & CAUSES 
 
With HPV being the most commonly transmitted STI but no assay for testing presence of 
all strains being available to the public, there has been a strong drive to understand the 
risk factors for contracting the virus. However, the virus is variable in nature, with 
hundreds of unique strains existing that can vary in terms of cell target type (mucosal or 
nonmucosal) and clinical outcome (oncogenic or nononcogenic) among numerous other 
factors (Trottier & Burchell, 2009). Thus, it comes with no surprise that an array of 
variables must be analyzed when predicting likelihood of infection.  
 
I. Gender 
 
For males, the most commonly cited risk factors are number of sexual partners, lack of 
sexual barrier use, history of previous STIs, lack of vaccination, and male circumcision 
(Goldstone et al, 2011). However, risk factors can vary across populations due to the 
presence of other infections or different disease patterns. For example, some studies have 
shown that being HIV positive is a significant predictor of being HPV positive, thus HIV 
status can also be said to be a risk for males living in Sub-Saharan Africa and other 
countries containing high HIV burdens (Goldstone et al, 2011).  
 
For females, proposed risk factors for HPV include high numbers of sexual partners, 
vaccination status, and misusing or not using barriers and contraception (Hernandez et al, 
2008). However, mechanisms not seen in males have also been proposed for etiology of 
the virus in female hosts, such as self-inoculation (hand and/or toy misuse from genitalia 
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to mouth) and sharing of material goods (especially lipsticks, makeup, etc) (Hernandez et 
al, 2008). Given that HPV is so readily transferred from person to person, improving 
upon population knowledge and awareness is an important need to combat spread. 
 
II. Age 
 
Besides sexual activity, age is also an important determinant, especially for females 
(Castle et al, 2006). Cervical cancer-related dysplastic cellular change is most often 
observed within the squamocolumnar junction, a landmark contained between the 
columnar epithelium of the endocervix and the squamous epithelium of the ectocervix 
within the female reproductive tract (Herfs et al, 2012). This epithelial metaplasia has 
been shown to most likely occur during puberty and/or the first pregnancy; after these 
periods, there is a sharp decline in infection likelihood, which is reflected by a decline in 
cervical cancer incidence in women above 30 years (Castle et al, 2006). Paradoxically, 
the prevalence of cervical cancer is higher in women over 35 years of age compared to 
younger groups, likely attributable to latency of pathogenesis after being infected at a 
young age (Herfs et al, 2012). In summary, while women above the age of 35 account for 
the largest burden of cervical cancer, the likelihood of having the necessary dysplastic 
change that leads to cervical cancer is more likely in females less than 30 years of age 
and especially those who are in puberty and/or first pregnancy. This indicates a 
disproportionately higher risk for HPV exposure in younger aged females.   
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III. Immunosuppression 
 
Because the primary immune response to HPV is cell-mediated, that is, involves the 
activation of phagocytes and T-cells rather than relying on antibodies secreted by B-cells, 
conditions that impair the immune cells of this system are also seen as risk factors (Burd, 
2003). For example, both renal transplantation and HIV-related immunosuppressions are 
just two such variables that suppress the cell-mediated immune response, thus affected 
individuals are considered to have an increased likelihood of HPV infection and 
especially of progression because they have an impaired defense system that normally 
combats pathogenesis (Bouwes & Berkhout, 1997). To put this into perspective, research 
suggests that the majority of renal transplant cases lead to HPV infection; women who go 
through this surgery are especially at risk with results showing a 14 times higher risk for 
cervical cancer, 50 times higher risk for vulvular cancer, and 100 times higher risk for 
anal cancer secondary to HPV infection (Hinten et al, 2012).   
 
Similarly, local immune suppression via dysplastic change in lung and esophageal 
epithelia by exposure to cigarette smoke mutagens also promotes ideal environments for 
HPV. Of interest, studies have shown that individuals are at an exponentially higher risk 
of developing high-risk HPV related oral squamous cell carcinoma if they partake in 
smoking for various years (Dayyani et al, 2010). Smoking, as well as alcohol 
consumption, is also of special interest because overuse leads to compromised mental 
states that can cause one to conduct risky sexual practices, like having intercourse 
without a barrier, which vastly increases risk for contraction (Goldstone et al, 2011). 
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IV. Viral Co-infection 
 
Furthermore, studies show that in some cases, co-infection with other genitalia-targeting 
viral agents e.g. cytomegalovirus (CMV) and human herpesvirus 6 /7 can cause transfer 
of oncogenes and mutagenic factors between viruses to promote pathogenesis (Burd, 
2003). Of note, a case-control study conducted in 1993 showed that co-infection with 
CMV and HPV was more likely to be observed in patients with cervical cancer rather 
than control patients with uterine leiomyoma (Shen et al, 1993). While infection with 
CMV alone was not statistically correlated with higher risk for cervical cancer, the fact 
that the experimental group that was previously exposed to HPV on merit of having 
cervical cancer showed a higher prevalence of CMV suggests a synergistic interaction 
between the two viral agents (Shen et al, 1993).  
 
Interestingly, viral interaction can also have the opposite effect – co-infection with 
adeno-associated virus has been shown to reduce likelihood of cervical lesion growth 
(Burd, 2003). Studies show that adeno viral gene product Rep78 disrupts transcription of 
E6 and E7 by interfering with the binding of TATA binding protein to the p97 core 
promoter when initiating viral transcription specific for HPV (Coker et al, 2001). 
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III. CYTOLOGICAL CHANGES – HISTOLOGY & FUNCTION 
 
 
HPV infection ultimately leads to a variety of conditions that range from innocuous 
lesions to malignant cancers. New cases of infection begin in a benign stage that can be 
overcome through immunity, but can progress into worse symptoms if not screened 
and/or treated as recommended by national guidelines. 
 
Genital Tract 
 
 
Of all known HPVs, more than 30 strains directly affect the genital tract (Vambutas, 
DeVoti, & Nouri 2005). Various factors are involved in malignant transformation of 
cervical and penile epithelia, but infection by HPV alone is usually not sufficient – 
several cofactors and molecular events together will determine the rate of pathogenesis. 
Oncogenic strains in particular are known to cause precancerous malignancies, which, for 
cervical cases, are described at the histological (cervical intraepithelial neoplasia – CIN) 
and cytological (squamous intraepithelial lesions – SIL) levels (Solomon, Davey & 
Kurman, 2002). 
 
Women are screened for cervical growths through the Pap smear. The most common Pap 
result is the Atypical Squamous cell of Undetermined Significance (ASC-US), which 
indicates detection of abnormalities within cervical epithelial cells (Solomon, Davey & 
Kurman, 2002). These anomalies are generally termed dysplasia. Dysplasia can present in 
a variety of forms, such as cytogenetic change (dyskarosis) in the form of nuclear size 
changes and hyperchromasia, nuclear crowding due to changes in the number of 
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chromosomes (trisomies and monosomies) or whole genome multiplication (ploidy), 
formation of a perinuclear halo, and chromatin granulation (Kurman, 2012). Dysplasia 
can also present as cellular hyperproliferation leading to non-defined borders or presence 
of parakeratosis or hyperkeratosis (Solomon, Davey & Kurman, 2002). These changes 
are collectively called the HPV cytopathic effect, also known as koliocytosis, and an 
HPV-infected irregular epithelial cell containing these changes would be termed a 
koliocyte (Kurman, 2012). Koliocyte presence is a key finding observable in even the 
early stages of HPV infection (Figure 6). 
 
 
          
 
 
Figure 6. Histological findings of the HPV cytopathic effect. Slide stained in a hematoxylin-
eosin dye, showing koliocytes in the center. Abnormal cells appear pyknotic with a clear halo. 
Cells also present with a higher cytoplasm-nucleus ratio with shrunken, hyperchromatic, and 
raisin-shaped nuclei. Figure adapted from Xavier, Bussoloti Filho & Lancellotti, 2005.  
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ASC-US lesions are classified into four categories depending on the level of dysplasia. 
The first result, atypical glandular cells (AGC), indicates malignancy of the glandular 
cells that line the inner cervical canal and uterus. This dysplasia would progress into an 
adenocarcinoma, not a squamous cell carcinoma, due to it being a malignancy of a 
columnar secretive cell (Singh, 2014). The second result, atypical squamous cells cannot 
exclude HSIL (ASC-H), indicates presence of dysplastic cells but cannot be definitively 
labeled as either low grade (LSIL) or high grade (HSIL) through Pap result alone, and as 
such would require more extensive testing for categorization (Burd, 2003).  
 
The third result is low-grade squamous intraepithelial lesions (LSIL), which indicates 
cells with minor dysplasia that usually clear by natural immunity – 2/3 of lesions regress, 
1/6 remain stable, and 1/6 progress to higher grade dysplasia (HSIL) (Burd, 2003). LSIL 
changes are the beginning of the mutagenic process. That is, minor cytological dysplasia 
is visible through changes in cell appearance, shape, size (atrophy or hypertrophy), 
numbers (hyperplasia), or type (metaplasia) (Burd, 2003). Because the changes are low 
grade, the cells still resemble their natural state but slight abnormalities as above are 
visible. At this stage, the mildly dysplastic cells can be described as LSIL when viewed 
histologically or cervical intraepithelial neoplasia type 1 (CIN 1) when discussed 
cytologically (Munoz et al, 2006). 
 
Finally, the fourth possible result is high-grade squamous intraepithelial lesions (HSIL), 
which suggests more severe dysplastic change and are more likely to be associated with 
precancer. HSIL cells display high levels of dysplastic change reflecting those described 
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in the previous section and are inherently more aggressive, with up to 1/3 of such lesions 
becoming invasive within a decade (Burd, 2003). An HSIL patch of cells will show 
changes in the majority of the epithelium when viewed under magnification. In this state, 
the dysplasia is at much greater levels than as seen in LSIL. Both the majority of the 
affected cell(s) as well as the majority of the affected physiological region(s) will show 
severe abnormalities (Burd, 2003). Precancerous lesions that display such changes can be 
described as HSIL when viewed histologically, or CIN 2 or CIN 3 when viewed 
cytologically (Burd, 2003).  
 
By the definition of being a stage of ‘precancer’, HSIL cells are still contained within the 
epithelium because they have an intact basement membrane (Munoz et al, 2006). Due to 
this containment, such growths are often used interchangeably with carcinoma in situ, a 
benign neoplasm of other organ systems that is still contained to the epithelium and is a 
requisite step for primary tumor formation (Munoz et al, 2006). When further progressed, 
primary tumor cells can lose regional containment, piercing through the basement 
membrane that separates them from other bodily tissues; even further penetration can 
prove deadly, especially when cells break through a basement membrane surrounding a 
blood or lymphatic vessel (Ruoslahti, 1996). From there, the cells are free to metastasize 
across the body via the lymphatic and/or circulatory systems, colonize other areas of the 
body, and give rise to secondary tumors (Ruoslahti, 1996). Lesion classification based on 
these physiological differences between pre-cancerous and cancerous states (Figure 7) 
are key in making diagnostic and prognostic decisions for affected patients. 
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Figure 7. Cellular changes seen in transition to cancer. Low-grade changes (LSIL, CIN 1) 
include cells with minor alterations that still resemble the original cell. Cells display high-grade 
changes (HSIL, CIN 2 and 3) when they have severe changes and take up a larger portion of the 
region and cell itself. An HSIL transforms into cancer when it pierces the basement membrane, 
allowing it to metastasize to other organ systems. Figure taken from NZ Ministry of Health, 2005. 
 
 
 
Oral Tract 
 
 
HPV infection is also appreciated as a potential cause of oral squamous cell carcinoma 
(OSCC) and other head and neck squamous cell carcinomas (HNSCC). However, the 
HPV DNA detection rate in such lesions has varied across trials, so the issue is not well 
understood (Zhao et al, 2009). In general, testing for HPV in samples from the oral 
mucosa is difficult because the basal layer of the epithelium, where the virus remains 
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latent, is prone to sloughing off when a sample is taken (Speight 2007). That being said, 
oncogenic HPV DNA presence has been found in a variety of dysplastic oral epithelial 
conditions, making HPV suspect in oral epithelial dysplasia and indicating that it may 
play a role in OSCC carcinogenesis (Zhao et al, 2009). 
 
It is unknown if the relationship between HPV and OSCC is correlative or causal 
(Speight 2007), but results of recent studies have indicated that it is likely a case of the 
latter. Of note, one recent study showed that non-HPV related OSCC cases form due to 
mechanisms leading to mutagenic overexpression of the p53 pathway, while HPV-
positive OSCC cases inversely show very low rates of p53 expression (Chen et al, 2011). 
The authors attributed OSCC carcinogenesis to two separate pathways: well-known 
environmental toxins (betel nut, tobacco, alcohol) leading to p53-overexpressing lesions, 
or viral oncogenes (high-risk HPV viral oncogene E6) inhibiting p53 by tagging for 
ubiquitination, causing formation of low p53-expressing lesions (Chen et al, 2011). 
 
The dysplastic changes seen in oral lesions mimic those seen in cervical growths. 
Macroscopically, the affected area can appear with a different color, being bright red 
(erythroplakia), white (leukoplakia), or mixed red-white (erythroleukoplakia) 
(Lumerman, Freedman & Kerpel, 1995). The lesions can also vary physiologically, 
appearing as flat, verrucous, or papillary (Lumerman, Freedman & Kerpel, 1995). 
Furthermore, the epithelium can display ulcerations, which occur when areas of the 
epithelium are lost (George, 2011). Microscopically, lesions show architectural changes 
in the mucosa, evidenced by formation of rete ridges and hyperplasia in the lower third of 
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the epithelium which progresses into cytogenic atypia, cellular dispolarity, dyskeratosis, 
visible mitotic figures, and cellular pleiomorphism in the upper third of the region in later 
stage growths (Lumerman, Freedman & Kerpel, 1995). These lesions are placed into the 
same SIL categories and progress into oral squamous cell carcinoma if left untreated.  
 
Anal Tract 
 
 
Anal cancer is also biologically similar to cervical cancer. Although more rare, the 
incidence of anal squamous carcinoma is rising in females and males, particular within 
high risk groups like men who have sex with men and individuals co-infected with HIV 
(Nyitray et al, 2011). Unlike HPV-related lesions in other mucosa, other anal lesions have 
been shown to be associated with HPV DNA presence; specifically, anal condyloma, a 
variant of grade 1 anal intraepithelial neoplasia, is also observed with present HPV6 or 11 
DNA (Wells et al, 1988).  
 
After infection with HPV, dysplasia can present along epithelia of the anal canal or the 
more external perianal skin (Abbasakoor & Boulos, 2005). Dysplasia in this case is also 
graded on the SIL scale and shares similar cytological changes in structure and 
appearance as discussed in the prior section on cell cytology. However, a two-tiered 
classification system also exists for anal lesions - along with being described as an SIL, 
these growths can also be described on the anal intraepithelial neoplasms (AIN) scale, 
which is characterized between levels 1 and 3 on grade of severity (Kreuter et al, 2008). 
Generally, anal LSIL overlaps with AIN 1 and 2, and more severe anal HSIL overlaps 
with AIN 2 or 3 (Kreuter et al, 2008). If an AIN 2 growth stains positive for the 
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p16INK4A tumor suppressor (released from inhibition by unbound e2F in the pRb 
cascade, as a result promoting passage of the G1/S checkpoint), it is classified as a 
moderate dysplastic HSIL given that it is more likely to be in a proliferative state if 
higher levels of p16INK4A are detectable; otherwise, it will be classified as a lower 
grade LSIL (Bala et al, 2013). If untreated, the most severe of these lesions worsen into 
invasive anal squamous carcinoma. The type of HPV can have a direct influence on the 
presence of AIN – in total around 30 HPV types are linked to AIN, but the severity varies 
with HPV genotype (Echenique & Phillips, 2011). For example, HPV 6 and 11 are the 
cause of over 90% of exophytic low-grade (AIN 1) lesions while HPV 16 and 18 are 
responsible for the majority of severe dysplastic lesions (AIN 2 or AIN 3) and 
consequently cases of anal cancer (Echenique & Phillips, 2011). 
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IV. PATHOGENESIS, CLASSIFICATION, & DETRIMENT 
 
 
Genital Tract 
  
 
For genital growths, patients rarely experience major symptoms early on. Perhaps the 
most noted symptom is the appearance of usually painless warts. In women, warts usually 
appear on the vulva but can also present on the cervix; in men, warts often appear on the 
penis or scrotum (Drake et al, 1995). Warts are mostly benign and usually cause itching 
or burning, rarely causing of any major discomfort (Drake et al, 1995). As infection 
progresses to an early stage lesion, a variety of symptoms arise. Of note, one may 
experience pain during intercourse, runny discharge, hematuria, incontinence, and 
hormonal dysregulation changes such as fatigue, weight loss, appetite loss, or bone pain 
(Drake et al, 1995). Most commonly, women experience vaginal bleeding outside of 
normal menstruation (Drake et al, 1995). 
 
Staging and grading are two techniques used to classify lesion severity. Grade is based on 
the degree of anaplasia, or cellular differentiation, in neoplastic cells. Well differentiated 
or grade 1 tumors are demarcated, contain clear boundaries, and resemble the parent cell, 
making them low severity (Shingaki et al, 1988). Grade 3 tumors are poorly 
differentiated or depart from normal appearance, making them more severe and 
aggressive, while moderately differentiated grade 2 tumors lie between the two (Shingaki 
et al, 1988). Stage, on the other hand, indicates extent of growth – it measures size, 
metastases, and systemic spread; in general, determination of treatment modality and 
prognosis is more influenced by stage than grade (Hojo et al, 1982).  
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Cervical lesions fall into stage 0 (carcinoma in situ), stage 1 (limited to cervix), stage 2 
(extension to uterus/vagina), stage 3 (extension to pelvic wall and lower vaginal third), or 
stage 4 (extension to organs beyond the pelvis) tumors (López-Arias et al, 2017). 
Cervical cancers have been observed to metastasize to lymph nodes and adjacent tissues 
(uterus, vagina, ovary) and more uncommonly spread to the urinary system (ureters and 
bladder), adrenal glands, liver, or lung (López-Arias et al, 2017). 
 
Penile carcinomas have a similar staging system. In stage 1, the proliferation is confined 
to the glans, but will spread by invading the penile shaft or corpora, indicating a stage 2 
growth (Burgers, Badalament & Drago, 1992). The tumor becomes stage 3 after it 
metastasizes to the inguinal lymph node but remains operable. Once the tumor invades 
adjacent structures and become inoperable, it becomes stage 4 (Burgers, Badalament & 
Drago, 1992). Penile tumors have a different metastatic pattern – the tumor will spread 
lymphatically to groin nodes and intrapelvic nodes, causing metastasis to the lungs and 
liver and sometimes to the bone, brain, and skin (Srinivas et al, 1987). Tumors of the 
urethra, prostate, bladder, and rectum are most commonly observed to metastasize to the 
penile region and cause secondary penile carcinoma (Srinivas et al, 1987). 
  
Oral and Anal Tracts 
 
 
The TNM staging system used for oral and anal lesions differs from that of genital 
lesions. This system begins at stage T0, which indicates no evidence of tumor. From 
there, stage Tis indicates a mucosa-confined carcinoma in situ, T1 indicates a tumor 
<2cm, T2 indicates a tumor between 2-4cm, and T3 indicates a tumor >4cm (Wittekind, 
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2011). Stage T4a indicates a tumor invading more superficial structures of the epithelium 
(facial skin, floor of mouth, cortical bone, etc.) while stage T4b indicates a tumor that has 
invaded deeper structures (pterygoid bone, skull base, etc.) (Wittekind, 2011).  
 
Anal lesions secondary to HPV can present in a variety of regions. Most common regions 
include outer anal skin (visible 5 cm away from the anal opening), the perianal region 
(visible within 5 cm of the anal opening), the anal canal itself (visable through anoscopy), 
or the transformation zone (proximal to the pectinate line, which separates the inner 2/3 
of the anus from the outer 1/3) (Echenique & Phillips, 2011). Patients affected by anal 
lesions present with a variety of symptoms, including itching, anal discharge, discomfort 
and/or tenesmus (recurrent desire to empty the bowels) (Echenique & Phillips, 2011). 
The clinical appearance of an anal lesions can be difficult to spot, but most often patients 
appear with swelling, flaking, oozing, or a scaled, white, or pigmented anal area 
(Echenique & Phillips, 2011).  
 
If patients do not follow proper screening and treatment guidelines for AIN (high 
resolution anoscopy or colonoscopy in combination with watchful waiting, topical 
therapy e.g. 5-flourouracil, photodynamic therapy, cryotherapy, and/or surgery/ablation), 
lesions can progress into squamous cell carcinoma (Osborne et al, 2014). When 
progressed to a metastatic state, anal carcinomas take advantage of the lymphatic system 
proximal to the pectinate line to invade the inferior mesenteric lymph nodes and nodes 
along the internal iliac vessels, or invade lymphatic drainage distal to the pectinate line to 
invade the inguinal nodes (Osborne et al, 2014). Anal cancers are most often observed to 
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spread to the liver, lungs, and less commonly the brain and skeletal system through these 
lymphatic drainages (Sundermeyer et al, 2005). 
 
Dysplasia of the oropharyngeal cavity results in oozing sores, lumps, thickening of the 
mouth lining, loose teeth, or diffuse pains of the tongue, lips, jaw, and throat (Bagan, 
Sarrion & Jimenez, 2010). As the lesions increase in size, patients experience sharper 
pain, dysarthria, and dysphagia (Bagan, Sarrion & Jimenez, 2010). The oral cavity 
contains extensive lymphatic networks, and lesions take advantage of this to metastasize 
to nodes within the neck and distant structures like the lung; common origin sites of 
secondary oral lesions are the breast, lung, and kidney (Van der Waal & Buter, 2003).  
 
Generational Transmission of HPV and Related Cancers 
 
 
Studies have shown a prevalence of 11.2% of HPV DNA presence in newborns up to 3 
months of age from HPV positive mothers (Trottier et al, 2016). Thus, the prenatal, 
perinatal, and postnatal routes of transmission are also an important point of interest. 
Most cases of vertical transmission from parent to child occur during delivery or 
caesarean section from contact of the fetus with maternal cells after early membrane 
rupture. This is the most common source of transmission, with studies on pregnant 
women showing HPV DNA within the amniotic fluid of a small proportion (15%) of 
pregnant infected women (Trottier et al, 2016) and a prevalence of HPV DNA due to 
exposure to these fluids in 15% of placental samples taken from HPV positive mothers 
during prenatal testing (Park et al, 2012).  
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Other theories exist regarding vertical transmission, but have much less support. 
Transmission in utero is one possibility, with ascending infection from the mother’s 
system or infected semen following intercourse possibly causing infection of a fetus 
(Park et al, 2012). However this is unlikely, as HPV DNA was only detectable in 8% of 
spermatozoa taken from seminal fluid samples in studies investigating this theory 
(Laprise et al, 2013). Perhaps even more of a reach, HPV has been found within breast 
milk at miniscule levels – in a recent study, 2/80 (2.5%) of HPV infected mothers had 
detectable HPV DNA in their milk. But, for both patients HPV was not detected in either 
the uterine or oral of the child after birth, indicating that the theory of transmission via 
suckling is unlikely (Trottier et al, 2016).  
 
Of interest, important factors related to perinatal transmission are theorized to be viral 
load, number of genital lesions, and coinfection with multiple genotypes (Trottier et al, 
2016). Transmission was also found to be associated with vaginal delivery, spontaneous 
abortion, prematurity, and preterm delivery, but the mechanisms for these routes of 
infection are less understood (Trottier et al, 2016). Further studies on the consequences of 
HPV infection in pregnancy outcomes are thus needed in order for us to develop better 
guidelines for pregnant women that face these risks during child labor (Trottier et al, 
2016). 
 
In relation to HPV-related cancers, a number of generational transmission patterns have 
been observed. One study showed that a lesion is more likely to occur due to genetic 
linkages with parents rather than environmental toxins in Swedish families (Magnusson 
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et al, 1999). In this study, comparing mono- and dizygotic twins implicated that a genetic 
link to cervical cancer may exist. Of note, familial cases of cervical cancer usually have 
an earlier age of onset than sporadic cases, although this may be a bias related to relatives 
having a higher and earlier tendency to report for physical exam (Magnusson et al, 1999). 
However, no difference in mean age at diagnosis between first- and last- siblings was 
found, and this lends support to a possible genetic component (Magnusson et al, 1999). 
 
While no genome-wide studies have implicated a specific gene for cervical cancer and/or 
HPV persistence, there may be variants that could be linked to the disease. Indeed, 
studies have found genetic loci that may be related to transmission, such as a recent study 
of Han Chinese groups showing a possible correlation between cervical cancer risk and 
the 4q12 and 17q12 gene loci (Shi et al, 2013). Further such studies are needed to 
develop upon our insights on HPV-related cancer susceptibility.  
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V. CONTINUITY OF CARE 
 
 
Detection 
 
 
Through the Pap smear, one can detect whether a patient’s cervical epithelia is within 
normal levels or if it shows malignancy, that is, shows the presence of SIL. From there, a 
biopsy may be taken to probe severity of change to assess whether the cells are in a 
precancerous or cancerous stage. CIN 1 describes cells showing low-grade changes that 
will likely be cleared through cell-mediated immunity (Burd, 2003). CIN 2 describes 
moderate changes, which need to be observed over time due to the possibility of further 
change (Burd, 2003). Finally, CIN 3 describes severe high-grade lesions, which have the 
highest probability for progressing to cancer and are thus described as precancerous 
(Burd, 2003).  
 
The decline in mortality rate due to invasive cervical cancer can be contributed to better 
and earlier detection of the cancer precursor, CIN. If a patient presents with an abnormal 
Pap biopsy indicating possible CIN, a repeat Pap or co-test, which consists of a Pap and a 
HPV reflex test that examines cells for HPV DNA presence through rapid polymerase 
chain reaction test (PCR), is recommended within 1 to 3 years (Katki et al, 2013). 
Patients may be followed up by Colposcopy, an invasive procedure that examines the 
cervical lining with a magnifying device (Katki et al, 2013). If a patch of dysplastic cells 
is found, a sample is taken using an instrument and sent for testing of CIN presence and 
grading. If a patient shows an AGC result, a sample of the Endometrium or the inner 
uterus, may also be taken for biopsy (Katki et al, 2013).  
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Currently, HPA DNA testing is a very useful tool. However, while the pathways for 
cytological atypia are well researched, malignancies can still be missed by even the most 
experienced of healthcare providers. To complicate the issue further, patients who are 
borderline or display mild dysplasia may benefit from a colposcopy or second biopsy, 
despite only showing signs of early infection (Katki et al, 2013). Earlier detection of CIN, 
whether through traditional means or invasive measures, aids in improving prognosis for 
patients (Katki et al, 2013). 
 
Acute Treatment 
 
Oncogenic HPV genotypes represent only a small proportion of strains, and in most cases 
the virus is cleared by cell-mediated immunity with no lasting detriment. However, for 
the cases that do progress into viral latency within the mucosa, intervention is needed to 
prevent tumorigenesis.  
 
Genital warts are a common manifestation of low-risk, non-oncogenic HPV. Warts can 
vary in nature, being raised or flat, pink or flesh-colored, and variable in shape, size, and 
location (Drake et al, 1995). There is often a latent period between which dysplasia 
manifests as a wart; while this time period is variable, warts usually take up to 3 months 
post viral exposure to manifest (Drake et al, 1995). Warts often clear naturally, but care-
providers have an array of treatments for these lesions. One can be prescribed a topical 
cream that destroys wart tissue to provide relief, commonly used of which are Podofilox 
and Imiquimod (Uyar & Sacar, 2014). Warts can also be removed physically through: 
cryotherapy (freezing of affected area via liquid nitrogen), conization (physical removal 
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of affected area), laser therapy (burning away of affected area), or loop electrosurgical 
excision (removal via electric current) (Uyar & Sacar, 2014).   
 
HPV-related cancer treatments are specific to the affected epithelium and can consist of a 
unique combination of treatment measures based on the needs of the patient. Because a 
large variety of cancers can develop as a result of pathogenesis, including vaginal, 
vulvular, penile, cervical, and anal, a variety of targeted treatments are possible. Once 
grade and stage are determined, care-providers can decide on a plan for treatment 
consisting of surgery, radiation therapy, chemotherapy, and/or targeted therapy (Singh, 
2014).  
 
Prevention 
 
 
The most effective way of protecting oneself from HPV is vaccination, and currently 
three vaccines are available to the public. Most commonly, these vaccines all protect 
against HPV types 16 and 18, which account for the greatest risk for cervical cancer 
(Palefsky et al, 1991). Cervarix only protects against HPV 16 and 18, whereas Gardasil 
also protects against these and HPV9 and 11, which are suspect in 90% of genital wart 
cases (Verma & Khanna, 2013). Gardasil9 offers the same protection as Gardasil, but 
also protects against less common oncogenic strains like HPV strains 31, 33, 45, 52, and 
58 (Verma & Khanna, 2013). It is estimated that vaccination could have prevented up to 
70% of cervical cancer, 80% of anal cancer, 60% of vaginal cancer, and 40% of vulvular 
cancer cases (Verma & Khanna, 2013). Vaccination thus stands as the most effective 
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measure for preventing pathogenesis, and the WHO recently added the HPV vaccine to 
their recommended/routine vaccinations for all countries for this reason.  
 
One recommended practice is vaccinating girls aged 9-13, which would provide 
protection for up to 10 years, covering an age range that includes the routine age of 
sexual onset. Vaccinating the majority of the population still benefits the unvaccinated by 
the herd immunity effect, which mandates a large proportion (~95%) of participants in a 
population to be immune. In the United States, there has been a movement for increasing 
awareness on the importance of vaccines since they became available in 2006. In 2013, 
participation rates were still low with only 38% of girls and 14% of boys aged 13-17 
having received all three doses (Stokley, 2014). However, we have made progress, and in 
2016 there was a 6 of 10 participation rate nation-wide, with the least coverage seen in 
Texas and the most seen in states in the Northeast and California (CDC, 2017).  
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VI. BARRIERS TO CARE 
 
 
Health organizations have identified increased vaccine uptake to be a priority for making 
advances in coverage goals. In one study, surveys conducted in pediatric offices 
highlighted a number of barriers to vaccination. For patients and parents of patients, 
beliefs on bad reputation based on Internet research, concern about secondary health 
effects and vaccine safety, and implications about sexual behavior and beliefs on sexual 
onset were prominent (Dilley et al, 2017). For providers, brief appointment times, lack of 
reimbursement, and lack of accepted insurance were issues (Dilley et al, 2017). The study 
surveyed the clinicians on methods for overcoming these barriers and found that more 
outreach, more readily available educational materials for clinic staff and patients, 
implementing electronic medical record reminders and at-home visits, partnering with 
school clinics, and use of text message reminders and walk-in appointments were viable 
interventions (Dilley et al, 2017).  
 
Another study showed that low coverage rates lay not only on the fault of providers and 
parents, but are also influenced by barriers related to sexual and cultural beliefs. For 
males, there was a lack of perceived benefit from vaccination that stemmed from a lack 
of awareness about whom the vaccine is beneficial to (Holman et al, 2014). Furthermore, 
given that there is a preference for promoting herd immunity by vaccinating girls, another 
issue seen was not receiving a provider’s recommendation to vaccinate due to being a 
male (Holman et al, 2014). In relation to heritage, it is interesting that beliefs on the 
benefits of vaccination varied among ethnocultural groups. For example, despite Hispanic 
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women having rather high incidence and mortality rates due to cervical cancer, some 
subgroups have favorable attitudes towards vaccination and higher coverage rates, while 
others have opposite beliefs (Luque, Raychowdhury & Weaver, 2012). Non-favorable 
attitudes on perceived benefit may be confounded by lack of insurance coverage, distrust 
of the healthcare system, language barriers, and health practices adapted from living in 
other countries especially when looking at immigrant groups (Luque, Raychowdhury & 
Weaver, 2012).  
 
There exists evidence that racial disparities exist in coverage rates. In 2013, only 30.6% 
of African Americans females and 30.3% of Hispanic females aged 19-26 initiated the 
vaccine, in comparison to nearly 42% of White females and 43.1% of females who 
indicated ‘other’ race being vaccinated (Table 1). Reviewing interventions for 
overcoming such racial disparities, one study found that multicomponent and gender-
tailored interventions were needed over traditional interventions to target specific ethnic 
groups (DiClemente et al, 2015). Variation across ethnic groups was linked to low access 
to care, variable beliefs on vaccination, and issues with cost, so the study attempted to 
overcome these barriers by creating an intervention in communities of color with 
immediate and free access to the vaccine. But, uptake still remained poor, with only 12% 
of participants receiving the first dose (DiClemente et al, 2015). This highlights more 
intangible barriers to vaccination, such as clinic availability with opening times 
coinciding with school, having multiple doses that must be adhered to over many months, 
and the patient-provider relationship (DiClemente et al, 2015). The idea of the patient-
provider relationship is linked to levels of trust and respect, but because such interactions 
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cannot be monitored due to patient confidentiality, this is a difficult obstacle to overcome 
and represents an area in need of further study (DiClemente et al, 2015).  
 
        
 
 
Table 1. Proportion of adults in the United States who received the HPV vaccine in 2013, 
stratified by age and race. Findings of this study show that among other variables, patient race 
and ethnicity were linked to disparities regarding likelihood for HPV vaccine acceptability and 
initiation. Results were tested at a 95% confidence level. Table taken from Williams et al, 2015. 
 
 
Another area in need of further exploration is how socioeconomic status and income play 
into decision-making and beliefs regarding need for vaccination. Current research has 
shown varied conclusions regarding the effect of socioeconomic status on beliefs of 
parents and of patients themselves on HPV vaccine acceptance (Brewer & Fazekas, 
2007). Of note, five major studies conducted in the United States between 2004 and 2007 
showed that lower levels of parental education indicated higher vaccination acceptance 
for a child or for oneself, while two other studies completed in 2006 showed that 
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education was unrelated to acceptability (Brewer & Fazekas 2007, Constantine & Jerman 
2007). Also, two studies done in 2004 and 2006 showed that higher income level 
correlated with higher vaccine acceptability, but another done in 2006 did not find this 
effect as statistically significant (Brewer & Fazekas 2007, Davis et al 2004). Possibly 
related, parents who reported to public clinics were more likely to accept the vaccine than 
those who attended private clinics (Brewer & Fazekas 2007, Zimet et al 2005). 
Furthermore, two major studies showed that insurance status is unrelated to vaccine 
acceptability, but another done in the same time frame showed that parents who pay for 
healthcare out-of-pocket or through Medicaid were more likely to accept vaccination for 
their child than those that paid through other means (Brewer & Fazekas 2007, Zimet et al 
2005). Clearly, findings on socioeconomic status vary in comparison to those regarding 
race, culture, and sex, and given that HPV and its related cancers see their highest 
prevalence in regions of the world that are considered developing or low-income, this 
represents an area in dire need of further study.  
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VII. UPCOMING THERAPY – THERAPEAUTIC VACCINES 
 
 
While the currently available vaccines offer ample preventive coverage, new lesion 
therapies are showing promise for reversing infection. One such invention, therapeutic 
vaccination, is slated to be available within the next decade. Unlike preventive vaccines, 
therapeutic vaccines work by antagonizing oncogenes E6 and E7 (Corona Gutierrez et al, 
2004). E6 and E7 are essential to pathogenesis, thus these vaccines can be helpful for 
eradicating established tumor cells, which preventive vaccines cannot do and that 
comparable interventions like 5-FU are not completely potent enough for (Corona 
Gutierrez et al, 2004). Currently, one therapeutic vaccine exists, called the MVA-E2 
vaccine. The vaccine is made from a recombinant form of the viaccinia virus Ankara 
(MVA) and contains the bovine papilloma virus E2 protein (Corona Gutierrez et al, 
2004). It has been proven to stop tumor growth in mice and rabbits, thus it is now in 
phased trials, results of which have been very positive (Rosales et al, 2014).  
 
Clinical Evaluation 
 
In a phase I/II trial for CIN 1 to 3 lesions, of 36 women who received MVA-E2 through 
intrauterine injection, 94% (34 women) showed elimination of lesions and only 2 women 
showed reduced grade from CIN 3 to 1 (Corona Gutierrez et al, 2004). Also, half of the 
patients showed elimination of HPV DNA and the other half showed regression of viral 
load to less than 10% of the original value (Corona Gutierrez et al, 2004). In a later phase 
II trial for CIN 2 and 3, results showed 54% (19 of 34) of patients with elimination of 
precancerous lesions and 32% (11) with lesion regression by 60-90% (García-Hernández 
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et al, 2004). In yet another phase I/II trial focusing on urethral lesions in men, 93% (28 of 
30) of patients had elimination of lesions and HPV DNA presence, and no recurrence was 
noted for a year; for only 7% (2) patients did the lesion not regress (Carvajal et al, 2007). 
In comparison, the control group of 20 patients on the current treatment of 5-FU 
(intravenous or as a topical ointment to the lesion) had 65% (13) of patients with lesion 
elimination, but the first lesion recurred within 3 months of treatment (Carvajal et al, 
2007). 
 
In a recent phase III study with a large patient sample (3000), ano-genital lesions varying 
from CIN 1 to 3 were evaluated (Rosales et al, 2014). In total, 1176 female and 180 male 
patients were injected with recombinant MVA E2 particles into various mucosal sites 
while the other half of the sample consisted of control patients that were administered 
more conventional therapies (cryosurgery, laser, conization, electrosurgery, 0.5% 
podophillin, trichoroacetic acid, or 5-FU). In the end, the experimental group had 89% 
(1051) of female patients with elimination of lesions and 2.4% (28) patients with 
regression to CIN 1, while all male patients showed elimination (Rosales et al 2014, 
Table 2). Also, the majority of samples showed a cytotoxic response against transformed 
cells, with HPV DNA being undetectable in 83% of samples (Rosales et al 2014, Figure 
8). The cytotoxic response formed in MVA-E2 patients was more potent than those 
formed in the control patient group as well, as lesion recurrence was much less prevalent 
in MVA-E2 patients than control patients (Rosales et al 2014, Figure 9). This suggests 
that MVA E2 is capable of both reversing lesions and inducing a response against 
compromised host cells (Rosales et al, 2014).       
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Table 2. Regression of lesions post MVA-E2, stratified by previous treatment and lesion 
type. Histological diagnosis showed that 94.3% (825/840) of LSIL patients and 73.3% (220/300) 
of HSIL patients were completely clear of lesions after the 14-week MVA-E2 regimen. Of those, 
only 5.2% (45) of LSIL patients and 17.33% (52) of HSIL patients had signs of persistent 
koliocyte presence after the treatment was complete. Table taken from Rosales et al, 2014. 
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Figure 8. Cytotoxic response against HPV+ cells after MVA E2. Bold lines indicate 
lymphocyte response against HPV DNA prior to MVA E2 and un-bolded lines indicate 
cytotoxicity post treatment. Data was obtained after 8-hr incubation in which effector cells 
stimulated by HPV antigens were mixed with infected cells. Determination of cytotoxic response 
level was derived from cellular lysis level measured from lactate dehydrogenase (LDH) release in 
a sample at several effector-to-target concentration ratios. Figure taken from Rosales et al, 2014. 
 
   
 
 
Figure 9. Recurrence of lesions in control and MVA E2-treated patient groups. Filled in 
symbols indicate recurrence rates for control patients who were treated by conventional therapies 
(cryosurgery, laser, conization, electrosurgery, podophillin, trichoroacetic acid, or 5-FU). Open 
symbols indicate recurrence rates for patients treated with MVA E2.  Data was collected up to 2 
years post treatment. The differences in recurrence index for each experimental group were found 
to be statistically significant at p≤0.008 via student's t-test. Figure taken from Rosales et al, 2014. 
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VIII. DISCUSSION/CONCLUSION 
 
 
HPV and its related cancers were once serious health issues across the world, but over the 
past few decades, we have made major strides in protecting at-risk populations from 
exposure. The advent of the Gardasil and Ceravix vaccines have been especially key in 
decreasing incidence, however barriers to vaccination still exist in modern society that 
prevent us from reaching herd immunity both in developing countries and domestically.  
 
Throughout this paper, I reviewed the pathways of infection and cancer formation, 
described the currently offered prevention and treatment measures, and explored a new 
therapy that may revolutionize the way we prevent HPV-related cancers. While the MVA 
E2 vaccine and other therapeutic vaccines are still coming to the limelight, they offer 
potential for overcoming difficult challenges to HPV and cancer prevention. Though they 
offer little in terms of prevention of spread of HPV, they could act as a significant 
alternative treatment measure, especially so for slowing lesion progression and cancer 
onset. There are, however, many areas that must be further explored before this treatment 
may become mainstream.  
 
 Upon analysis of most MVA-E2 related studies presented throughout this paper, a 
majority of patients were had total remission of lesions, but a small proportion of patients 
were only able to achieve regression of lesion grade. While impressive in both senses, the 
cytogenic differences in such patients must be assessed to understand what factors into 
this disparity. This is especially the case for anal and oral lesions in which HPV DNA has 
been implicated, for which assessment of the MVA E2 vaccine has yet to be explored 
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through a large-scale study. Given that the two preventive vaccines are so effective in 
preventing malignancies in these anatomical regions, this could be a major downside if 
newer vaccines turn out to be not as potent at providing protection to the oral and anal 
mucosa to all individuals.  
 
However, if it does turn out to be the case that this disparity is unavoidable, one possible 
method for overcoming these potential issues is use of combination therapy. By coupling 
the HPV therapeutic vaccine with approaches such as chemotherapy, radiation, or other 
bio-agent treatment, it is possible to enhance the vaccine effect. Co-treatment with 
epigallocatechin-3-Gallate, a chemotherapeautic chemical collected from green tea 
leaves, has been shown to induce targeted tumor cell apoptosis and enhance the cell-
mediated immune responses that HPV therapeutic vaccines promote in order to revert 
lesion growth (Hung et al, 2008). Another study showed that administering the vaccine in 
the presence of CpG oligonucleotide adjuvant with chemotherapy had an inhibitory effect 
against established viral E7-expressing tumor cells (Hung et al, 2008). Furthermore, the 
effects of vaccination could also be bolstered through combination therapy with 
antibody-mediated blockade of factors that block T-cell activation by viral pathways, 
such as co-treatment to inhibit cytotoxic T lymphocyte antigen-4 (CTLA-4) and 
programmed cell death protein 1 (PD-1), which could potentially prolong anti-tumor T 
cell responses (Hung et al, 2008). So, while the effect of therapeutic vaccines alone may 
prove to be insufficient, there certainly exist ways for us to boost their potency if 
necessary. 
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While the need for further studies as described exist, the vaccine has otherwise shown 
substantial therapeutic potential in a variety of regions. One downside of currently 
offered preventive HPV vaccines is the potential for side effects. Of note, vaccination 
may be linked with various negative outcomes, like spontaneous bruising or internal 
bleeding, dizziness and loss of consciousness, joint pain, and immune deficiencies like 
Guillain–Barré syndrome (Gee et al, 2011). While there have not been any substantial 
studies focusing on the rates of these side effects, numerous studies examining the rates 
and severity of side effects in other vaccines have been conducted. Of note, a major study 
focusing on the seasonal Influenza vaccine showed that in a sample of 849 subjects, 
35.2% of placebo patients and 34.1% of vaccine patients presented with >1 symptom 
among fever, myalgia, fatigue, malaise, or headache (Nichol et al, 1996). Despite this, the 
majority of complaints were mild local reactions that cleared on their own and only 
resulted in less use of the afflicted body region, and multivariate modeling showed that 
the vaccine was not statistically associated with increased frequency of these symptoms 
(Nichol et al, 1996). While one may assume such studies would alleviate the concerns of 
those seeking to vaccinate, such concerns are still prevalent in patients and parents of 
patients even today, so having alternative therapies not linked to unwanted symptoms 
would be paramount for overcoming these issues. Connected to this, administration of 
MVA E2 vaccine has not been shown to be linked with seriously adverse events during 
any study; of note, the only side effects seen were flu-like symptoms or pelvic 
discomfort, which are both considered grade 1 adverse events according to the National 
Cancer Institute’s CTCAE (Common Terminology Criteria for Adverse Events) and thus 
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required no intervention (Rosales et al, 2014). Grade 2 (moderate) events would have 
required noninvasive intervention, grade 3 (severe) events would have shown non-life 
threatening symptoms of significance, and grade 4 (life-threatening) events would have 
required urgent intervention, but none were noted throughout the study (Rosales et al, 
2014). While much more clinical testing is needed to explore the range of possible side 
effects related to MVA E2 administration, this offers substantial promise in overcoming 
negative attitudes on side effects regarding the more mainstream methods of HPV 
vaccination. These reported symptoms are identical in grade to those seen in the 
Influenza vaccine study, and if the wide acceptance and uptake rate of the Influenza 
vaccine across the world can act as any sort of indicator of the potential for MVA E2 
uptake, the novel therapy holds much promise for solving coverage issues faced by the 
currently offered HPV vaccines.  
 
Other intangible benefits of the vaccine include a shorter dosage schedule and less 
perceived stigma. Losing patients to follow-up due to the lengthiness of the Gardasil9 and 
Cervarix vaccine schedules (3 doses at 0, 2, and 6 months post initiation) remains a worry 
for providers. On the other hand, the MVA E2 vaccine is administered in a much shorter 
schedule (four doses on a single day once per week for 6 weeks for females, or instilled 
into the urethra of males once a week for 5 weeks), which may help with bolstering 
adherence rates to the vaccine schedule (Rosales et al, 2014). While further studies are 
needed to assess long-term protection, the shorter schedule could greatly aid in increasing 
coverage in communities. Furthermore, while only speculation, with the MVA E2 
vaccine being more targeted to reducing lesion grade than towards HPV prevention but 
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being very capable of doing so nonetheless, the stigma involved with the currently 
offered vaccines may not be as much an issue for vaccine uptake rates. Parents often 
decline vaccination for fear that their child may gain a false sense of safety for initiating 
intercourse post vaccination, building a sense of stigma that can cause one to decline the 
vaccine on behalf of his or her child. It is possible that with the proper messaging and 
awareness efforts, the MVA E2 vaccine could be perceived in a different light. This 
would allow incorporation of this vaccine as an alternative for such patients, which would 
prove beneficial for overcoming such obstacles and truly achieving herd immunity.  
 
Therapeutic vaccines hold great promise for treating HPV infection in the years to come. 
Not only does this treatment show signs of laboratory success, but it has also cemented its 
effectiveness in not only rodent models, but more importantly recent human trials. 
Besides having impressive precancerous growth and HPV DNA removal rates, the 
vaccine offers potential in overcoming psychologically perceived barriers to vaccination 
that are currently a major hindrance for coverage goals. As described above, there still 
remain several variables that need to be further studied before the treatment is perfected 
and can be introduced to modern clinical practice as a viable secondary therapy, but 
overall, the vaccine provides considerate therapeutic potential while proving to be a mild 
treatment. 
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